Menden Lab

Research focus

ERC Starting Grant · 2020

Predicting potent drug combinations by exploiting monotherapy resistance

Personalising treatments based on tumour genetic profiles enables cancer precision medicine. However, treating cancers using targeted therapies often fails due to the emergence of drug resistance. Here, my goal is to use drug high-throughput screens (HTS) combined with computational methods to identify resistance and its biomarkers, and to overcome it with smart drug combinations to empower cancer precision medicine. Identifying resistance in HTS is challenging: dissecting meaningful drug responses at high concentrations is impossible due to cytotoxicity, making non-responders and resistant cell lines indistinguishable, thus limiting resistance biomarker discovery to frequently mutated…

From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.